Stocks · Healthcare · Biotechnology
Celldex Therapeutics, Inc. CLDX
$31.65 -1.65% Close, Oct 2, 2026 · NASDAQ · Market cap $2.11B
Next earnings report: Nov 9, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $112,000, down 98.1% from a year earlier, slowing from -89.2% a quarter earlier.
- Operating margin narrowed to -290948.2% from -4053.7% a year earlier.
- The diluted share count rose 17.2% in a year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
Growth2Very weak
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 4%
- Revenue growth, 3-year CAGRBottom 10%
- Revenue growth accelerationBottom 19%
Quality6Very weak
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 29%
- Gross marginBottom 1%
- Operating marginBottom 1%
- Accruals (lower is better)Top 41%
Value24Very weak
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 40%
- Free-cash-flow yieldBottom 34%
- EBITDA / enterprise valueBottom 32%
- Sales / enterprise valueBottom 1%
Momentum52Neutral
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 31%
- 6-month returnBottom 44%
- 1-year return vs S&P 500Top 40%
- Distance from 52-week highTop 47%
- Trend checklist (0–4)Bottom 38%
Revisions64Neutral
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 32%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyTop 27%
- Upside to consensus price targetTop 35%
Stability53Neutral
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 35%
- Maximum drawdown, 3 yearsBottom 49%
- Beta vs S&P 500 (lower is better)Bottom 35%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -89.2% | -98.1% | ↓ |
| Gross margin | -2540.2% | -56850.9% | ↓ |
| Operating margin | -4053.7% | -290948.2% | ↓ |
| FCF margin | -3234.7% | -215908.0% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -98.1% | -89.2% | ↓ | Bottom 4% |
| Gross margin | -56850.9% | -2540.2% | ↓ | Bottom 1% |
| Operating margin | -290948.2% | -4053.7% | ↓ | Bottom 1% |
| Net margin | -268385.7% | -3446.9% | ↓ | — |
| Free-cash-flow margin | -215908.0% | -3234.7% | ↓ | — |
| Return on invested capital | -45.1% | — | Bottom 29% | |
| Revenue growth, 3-year CAGR | -14.0% | — | Bottom 10% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -8.3%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 30929.5%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +253.6 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -15.53%
- Shareholder yield
- -15.53%
- Share count change, 1 year
- +17.2%
- Share count change, 3-year CAGR
- +18.1%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- -7.1%
- Average 2-day reaction, last 8
- +3.8%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $66.80
- Target vs current price
- +111.1%
- Analysts with a rating
- 20
- Share rating Buy or Strong Buy
- 90%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | +11.3% | +1.2% | +9.3% | -3.8% | — |
| May 7, 2026 | -2.9% | -3.1% | -5.5% | -13.0% | +9.6% |
| Feb 25, 2026 | -22.0% | +24.1% | +16.5% | +25.6% | +24.4% |
| Nov 10, 2025 | -14.8% | -1.0% | +11.6% | +30.1% | -1.4% |
| Aug 7, 2025 | +1.2% | -1.1% | +16.6% | +6.3% | +21.3% |
| May 8, 2025 | -8.0% | +3.2% | +0.2% | +3.3% | +15.3% |
| Feb 27, 2025 | +2.7% | -1.6% | +2.3% | -5.1% | -1.3% |
| Nov 6, 2024 | +7.2% | +8.7% | +6.2% | +4.5% | -9.0% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.94 | -$1.06 | +11.3% | $22,000 |
| May 7, 2026 | -$1.18 | -$1.15 | -2.9% | $15,000 |
| Feb 25, 2026 | -$1.22 | -$1.00 | -22.0% | $100,000 |
| Nov 10, 2025 | -$1.01 | -$0.88 | -14.8% | — |
| Aug 7, 2025 | -$0.85 | -$0.86 | +1.2% | $730,000 |
| May 8, 2025 | -$0.81 | -$0.75 | -8.0% | $695,000 |
| Feb 27, 2025 | -$0.71 | -$0.73 | +2.7% | $1.2M |
| Nov 6, 2024 | -$0.64 | -$0.69 | +7.2% | $3.2M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 18423.15× | — | — | Bottom 1% |
| Free-cash-flow yield | -11.48% | — | — | Bottom 34% |
| Earnings yield | -13.78% | — | — | Bottom 40% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -1.6%
- 200-day average slope (20 days)
- +2.7%
- Distance from 50-day average
- -17.3%
- Distance from 200-day average
- -2.1%
- RSI (14)
- 30.6
- Relative volume
- 1.20×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 46.9%
- Volatility vs own 5-year history
- 22th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.42
- Correlation with S&P 500
- 0.40
- Current drawdown from 1-year high
- -29.5%
- Maximum drawdown, 3 years
- -70.8%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Oct 4, 2021 | Apr 8, 2025 | -73.1% | 881 days | Not yet recovered |
| Mar 2, 2021 | Mar 30, 2021 | -34.0% | 20 days | 19 days (Apr 27, 2021) |
| Nov 27, 2020 | Jan 6, 2021 | -28.8% | 26 days | 20 days (Feb 4, 2021) |
| Apr 27, 2021 | May 13, 2021 | -20.4% | 12 days | 29 days (Jun 24, 2021) |
| Jun 29, 2021 | Jul 7, 2021 | -18.1% | 5 days | 3 days (Jul 12, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $2.11B
- EPS, diluted (TTM)
- -$4.36
- Revenue (TTM)
- $112,000
- 52-week range
- $22.10 – $45.14
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $4.7M | $2.4M | $6.9M | $7.0M | $1.5M |
| Gross profit | -$48.7M | -$79.9M | -$111.1M | -$156.5M | $1.5M |
| Operating income | -$71.2M | -$115.2M | -$154.5M | -$195.1M | -$287.4M |
| Net income | -$70.5M | -$112.3M | -$141.4M | -$157.9M | -$258.8M |
| EPS (diluted) | -$1.64 | -$2.40 | -$2.92 | -$2.45 | -$3.90 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.2M | $1.2M | $695,000 | $730,000 | $0 | $75,000 | $15,000 | $22,000 |
| Net income | -$42.1M | -$47.1M | -$53.8M | -$56.6M | -$67.0M | -$81.4M | -$78.7M | -$73.5M |
| EPS (diluted) | -$0.64 | -$0.71 | -$0.81 | -$0.85 | -$1.01 | -$1.23 | -$1.18 | -$0.94 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$60.9M | -$103.7M | -$107.3M | -$157.8M | -$210.9M |
| Capital expenditure | -$1.2M | -$1.8M | -$1.8M | -$1.9M | -$2.7M |
| Free cash flow | -$62.2M | -$105.6M | -$109.1M | -$159.7M | -$213.7M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $269.9M | $4.1M | $216.2M | $432.3M | $2.4M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $717.6M
- Total assets
- $782.3M
- Total liabilities
- $67.8M
- Total debt
- $4.9M
- Net debt
- -$42.5M
- Shareholders’ equity
- $714.6M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 8,953,127
- Days to cover
- 13.12
- Change vs previous report
- +3.6%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Feb 11, 2019
- 1-for-15
- Mar 10, 2008
- 1-for-12